Fig. 5.

miR-106a directly targeted CDH1 in ovarian cancer cells. a The putative binding sites between miR-106a and 3′ UTR of LMO3 were predicted by microT-CDS. b, c The relative luciferase activity in A2780 and OVCAR3 cells co-transfected with CDH1-WT or CDH1-MUT and miR-106a or miR-con was assessed by dual-luciferase reporter assay. d, e CDH1 expression in A2780 and OVCAR3 cells transfected with miR-106a or miR-con and coated with Ago2 or IgG antibody was measured by qRT-PCR. f The protein level of CDH1 in human ovarian epithelium cell line ISOE80 and ovarian cancer cell lines A2780 and OVCAR3 was measured by western blot. g, h The protein level of CDH1 in A2780 and OVCAR3 cells transfected with miR-con, miR-106a, anti-miR-con or anti-miR-106a (miR-106a inhibitor) was examined by western blot. ***P < 0.001